The popularity of Sildenafil initially drove a surge for major pharmaceutical companies, however recent changes present a uncertain outlook for those considering a stake. Lower-cost competitors are eroding profits, and https://jaysonmajf315015.blog4youth.com/41699132/the-blue-pill-and-big-pharma-a-volatile-play